{"disease":{"id":"bacterial-peritonitis","name":"Bacterial peritonitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":13,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"fusidic-acid","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"gentamicin","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"tigecycline","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tygacil","generic_name":"TIGECYCLINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"30S ribosomal subunit","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Tygacil works by binding to the 30S ribosomal subunit of bacteria, preventing the aminoacyl-tRNA from binding and thereby inhibiting protein synthesis."},{"drug_id":"tobramycin","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"cefepime","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"CEFEPIME","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":59,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"ampicillin","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cefepime-hydrochloride","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"Cefepime Hydrochloride","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":64,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"cefepim","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefepim","company_name":"University Hospital Tuebingen","drug_phase":"discontinued","molecular_target":"Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Acute bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"tygacil","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tygacil","generic_name":"Tigecycline","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial protein synthesis","drug_class":"Tetracycline","quality_score":10,"revenue":null,"mechanism":"Tigecycline is a tetracycline class antibacterial agent."},{"drug_id":"cefamandole","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefadole","generic_name":"CEFAMANDOLE","company_name":"","drug_phase":"phase_2","molecular_target":"Solute carrier family 15 member 1","drug_class":"cefamandole","quality_score":null,"revenue":null,"mechanism":"Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"nebcin","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"aztreonam","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"ertapenem","indication_name":"Acute bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invanz","generic_name":"ERTAPENEM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":70,"revenue":null,"mechanism":"Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ertapenem","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invanz","generic_name":"ERTAPENEM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":70,"revenue":null,"mechanism":"Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ceftolozane","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zerbaxa","generic_name":"CEFTOLOZANE","company_name":"Cubist Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":"Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"amikacin","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"norfloxacin","indication_name":"Acute bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Acute bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Acute bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ofloxacine","indication_name":"Acute bacterial peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Complicated Bacterial Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":31,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07429929","title":"Saudi Emergency Laparotomy Audit","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"King Faisal Specialist Hospital & Research Center","has_results":false},{"nct_id":"NCT04153604","title":"Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis","phase":"","overall_status":"COMPLETED","enrollment_count":841,"lead_sponsor_name":"Methodist Health System","has_results":false},{"nct_id":"NCT03362632","title":"A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIP Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04775420","title":"MPV and NLR as Predictors of SBP Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":332,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT04159870","title":"Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":322,"lead_sponsor_name":"Ospedali Riuniti di Foggia","has_results":false},{"nct_id":"NCT06026267","title":"Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT05850858","title":"Platelets to Lymphocytes Ratio and Monocytes to Lymphocytes Ratio as Predictors of Response to Treatment in Cirrhotic Patients With Spontaneous Bacterial Peritonitis.","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT06199843","title":"Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":280,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT07024355","title":"Predicting and Monitoring Spontaneous Bacterial Peritonitis in Cirrhotic Patients Using the Mansoura Scoring System","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT01059396","title":"Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT05511766","title":"Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT02468089","title":"To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT03702426","title":"Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT04208763","title":"A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT06827756","title":"Comparative Study of Secondary Prophylaxis for SBP","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT05401721","title":"Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis","phase":"","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT05696054","title":"Laboratory Diagnosis of Spontaneous Bacterial Peritonitis","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT06234046","title":"Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT04161768","title":"Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT03163745","title":"Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04273373","title":"Low Dose Albumin Versus Standard Dose Albumin in High Risk Spontaneous Bacterial Peritonitis.","phase":"NA","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT04168099","title":"Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT06679842","title":"Early Ascitis Parencentesis in SBP","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT03029078","title":"FEcal Transplant, a Hope to Eradicate Colonization of Patient Harboring eXtreme Drug Resistant Bacteria?","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Centre d'Investigation Clinique et Technologique 805","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}